[et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”4.4.5″][et_pb_fullwidth_image src=”https:\/\/farmolab.es\/wp-content\/uploads\/2020\/05\/cognex.jpg” alt=”Cognex” title_text=”Cognex” _builder_version=”4.4.5″][\/et_pb_fullwidth_image][et_pb_fullwidth_code _builder_version=”4.4.5″ custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false”][\/et_pb_fullwidth_code][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.4″ use_background_color_gradient=”on” background_color_gradient_start=”#d5611b” background_color_gradient_end=”#ffffff” background_color_gradient_direction=”90deg” custom_margin=”40px||0px||false|false” custom_padding=”0px||0px||false|false”][et_pb_row _builder_version=”4.4.5″ custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false”][et_pb_column type=”4_4″ _builder_version=”4.4.5″][et_pb_cta title=”Cognex\u00ae” _builder_version=”4.9.4″ header_font=”|||on|||||” header_font_size=”52px” body_font_size=”13px” background_color=”rgba(0,0,0,0)” text_orientation=”left” custom_margin=”||||false|false” custom_padding=”20px|0px|0px|0px|false|false” animation_style=”slide” animation_direction=”right” header_font_size_tablet=”” header_font_size_phone=”32px” header_font_size_last_edited=”on|phone”][\/et_pb_cta][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.4.5″][et_pb_row column_structure=”3_5,2_5″ _builder_version=”4.4.5″][et_pb_column type=”3_5″ _builder_version=”4.4.5″][et_pb_text module_class=”lista-naranja” _builder_version=”4.9.4″ animation_style=”slide” animation_direction=”bottom” text_font_size_tablet=”” text_font_size_phone=”14px” text_font_size_last_edited=”on|phone” header_3_font_size_tablet=”” header_3_font_size_phone=”18px” header_3_font_size_last_edited=”on|phone”]<\/p>\n

Cognex\u00ae<\/span> 30 Capsules used for<\/h3>\n

States related to age, cognitive impairment and memory.<\/span><\/p>\n

Cognex\u00ae<\/span> 30 Capsules<\/h3>\n

Cognitive functions are mental processes that allow us to perform any task. They include the ability to think, concentrate, pay attention, memorize, transform, elaborate and retrieve information to function properly.<\/p>\n

Cognitive function can begin to deteriorate naturally around of 50s. To help protect cognitive functions, it is necessary to maintain a healthy lifestyle (diet, exercise, reading, memory training, etc.) and modify habits and harmful lifestyles. The loss of oxidizing homeostasis leads to increased oxidative stress, this to cell death and thus to cognitive dysfunction in aging. Turmeric can help control oxidative stress and maintain nervous system function and mental balance.<\/strong><\/p>\n

Cognex\u00ae 30 capsules is a nutraceutical product based on Theracurmin\u00ae, a bioactive turmeric extract obtained through a specific formulation process, which improves its bioavailability to obtain its maximum benefits.<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”4.4.5″][et_pb_image src=”https:\/\/farmolab.es\/wp-content\/uploads\/2020\/05\/caja-cognex.jpg” alt=”Presentaci\u00f3n Cognex” title_text=”Presentaci\u00f3n Cognex” force_fullwidth=”on” _builder_version=”4.4.5″ animation_style=”slide” animation_direction=”right”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.4.5″ use_background_color_gradient=”on” background_color_gradient_start=”#d5611b” background_color_gradient_end=”#ffffff” background_color_gradient_direction=”90deg” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” collapsed=”on”][et_pb_row _builder_version=”4.4.5″ custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false”][et_pb_column type=”4_4″ _builder_version=”4.4.5″][et_pb_cta title=”INFORMATION” _builder_version=”4.9.4″ header_font=”|||on|||||” header_font_size=”52px” body_font_size=”13px” background_color=”rgba(0,0,0,0)” text_orientation=”left” custom_margin=”||||false|false” custom_padding=”20px|0px|0px|0px|false|false” animation_style=”slide” animation_direction=”right” header_font_size_tablet=”” header_font_size_phone=”32px” header_font_size_last_edited=”on|phone”][\/et_pb_cta][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.4.5″ collapsed=”on”][et_pb_row _builder_version=”4.4.5″ custom_margin=”||||false|false” custom_padding=”||||false|false”][et_pb_column type=”4_4″ _builder_version=”4.4.5″][et_pb_text _builder_version=”4.9.4″ header_3_font_size=”18px” text_orientation=”justified” animation_style=”slide” animation_direction=”bottom” text_font_size_tablet=”” text_font_size_phone=”14px” text_font_size_last_edited=”on|phone”]<\/p>\n

Uses:<\/h3>\n

Cognex\u00ae by Laboratorios Farmolab is a food supplement that can provide a neuroprotective effect.<\/p>\n

Certain pathologies associated with age are accompanied by a deterioration of cognitive functions, increasing neuroinflammation, and by an increased level of oxidative stress, causing cognitive deterioration, and\/or dysfunction in memory and other cognitive functions.<\/p>\n

In case of such pathologies, offering neuroprotection in order to minimise cognitive deterioration can be of great help.<\/p>\n

Presentation:<\/h3>\n

NATIONAL CODE (C.N.): 197024.4
Box of 30 capsules.<\/p>\n

Instructions for use:<\/h3>\n

It is recommended to take 1 or 2 Cognex\u00ae capsules per day with a glass of water.<\/p>\n

A minimum of 12 months is recommended, although this product can be taken on an ongoing long-term basis.<\/p>\n

It is suitable for gluten- and lactose-intolerant patients and diabetics.<\/p>\n

Store in a cool and dry place, away from light, at a temperature less than 25\u00b0 C. Avoid sudden changes in temperature. The expiration date is applicable to the product with the original packaging intact and properly stored. Keep out of reach of children under 3 years of age. Food supplements are not intended to replace a varied and balanced diet and a healthy lifestyle. Do not exceed the suggested daily dose. Do not take in case of hypersensitivity to one or more components of this product.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.4.5″ use_background_color_gradient=”on” background_color_gradient_start=”#d5611b” background_color_gradient_end=”#ffffff” background_color_gradient_direction=”90deg” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” collapsed=”on”][et_pb_row _builder_version=”4.4.5″ custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false”][et_pb_column type=”4_4″ _builder_version=”4.4.5″][et_pb_cta title=”Composition” _builder_version=”4.9.4″ header_font=”|||on|||||” header_font_size=”52px” body_font_size=”13px” background_color=”rgba(0,0,0,0)” text_orientation=”left” custom_margin=”||||false|false” custom_padding=”20px|0px|0px|0px|false|false” animation_style=”slide” animation_direction=”right” header_font_size_tablet=”” header_font_size_phone=”32px” header_font_size_last_edited=”on|phone”][\/et_pb_cta][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.4.5″ collapsed=”off”][et_pb_row _builder_version=”4.4.5″ custom_margin=”||||false|false” custom_padding=”||||false|false”][et_pb_column type=”4_4″ _builder_version=”4.4.5″][et_pb_text _builder_version=”4.9.4″ header_3_font_size=”18px” custom_padding=”0px|||||” animation_style=”slide” animation_direction=”bottom” text_font_size_tablet=”” text_font_size_phone=”14px” text_font_size_last_edited=”on|phone”]<\/p>\n

Theracurmin\u00ae 60mg<\/h3>\n

Is a Submicron Colloidal\u00a0 Dispersion Particles of Curcuminoids and Curcuminoids. Characterised by a very high level of absorbency and bioavailability, allowing it to cross the BBB and to reach the CNS.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.4.5″][et_pb_column type=”1_2″ _builder_version=”4.4.5″][et_pb_image src=”https:\/\/farmolab.es\/wp-content\/uploads\/2020\/05\/cognex-esquema1.jpg” alt=”Cognex Evolution” title_text=”Cognex Evolution” _builder_version=”4.4.5″][\/et_pb_image][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.4.5″][et_pb_image src=”https:\/\/farmolab.es\/wp-content\/uploads\/2020\/05\/cognex-evolucion-cognitiva.jpg” alt=”Cognex cognitive evolution” title_text=”Cognex-evolucion-cognitiva” _builder_version=”4.9.4″ custom_margin=”||0px||false|false” custom_padding=”||0px||false|false”][\/et_pb_image][et_pb_text _builder_version=”4.9.4″ text_font_size=”14px” custom_margin=”0px||||false|false” custom_padding=”0px||||false|false”]<\/p>\n

Adapted from Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo Controlled 18-Month Trial. Small et al. Am J Geriatr Psychiatry. 2018 Mar;26(3):266-277.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.4.5″ custom_margin=”||||false|false” custom_padding=”||||false|false”][et_pb_column type=”4_4″ _builder_version=”4.4.5″][et_pb_button button_url=”@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF9saW5rX3VybF9wYWdlIiwic2V0dGluZ3MiOnsicG9zdF9pZCI6IjI0NyJ9fQ==@” button_text=”Back” _builder_version=”4.4.5″ _dynamic_attributes=”button_url” custom_button=”on” button_text_color=”#d5611b” button_border_width=”1px” button_border_radius=”10px” button_icon=”%%19%%” button_icon_placement=”left” custom_padding=”|30px||30px|false|false”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.9.4″ use_background_color_gradient=”on” background_color_gradient_start=”#d5611b” background_color_gradient_end=”#ffffff” background_color_gradient_direction=”90deg” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” disabled=”on” collapsed=”on”][et_pb_row _builder_version=”4.4.5″ custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false”][et_pb_column type=”4_4″ _builder_version=”4.4.5″][et_pb_cta title=”SCIENTIFIC EVIDENCE ” _builder_version=”4.9.4″ header_font=”|||on|||||” header_font_size=”52px” body_font_size=”13px” background_color=”rgba(0,0,0,0)” text_orientation=”left” custom_margin=”||||false|false” custom_padding=”20px|0px|0px|0px|false|false” animation_style=”slide” animation_direction=”right” header_font_size_tablet=”” header_font_size_phone=”32px” header_font_size_last_edited=”on|phone”][\/et_pb_cta][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.9.4″ _module_preset=”default” min_height=”249.9px” custom_margin=”||-22px|||” custom_padding=”22px||40px|||” animation_style=”fade” animation_delay=”600ms” disabled=”on”][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.9.4″ _module_preset=”default” min_height=”247.9px” custom_margin=”-1px|auto|6px|auto||” custom_padding=”0px||0px|||”][et_pb_column type=”1_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” text_font=”||||||||” text_text_color=”#E09900″ text_font_size=”33px” text_line_height=”1em” header_3_font_size=”33px” text_orientation=”center” custom_margin=”||-1px|0px|false|false” custom_padding=”57px||0px|0px|false|false” header_font_size_last_edited=”off|desktop”]<\/p>\n

March<\/h3>\n

[\/et_pb_text][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” text_text_color=”#E09900″ text_font_size=”33px” header_3_font_size=”55px” min_height=”72px”]<\/p>\n

2018<\/h3>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_image src=”https:\/\/farmolab.es\/wp-content\/uploads\/2021\/04\/Recurso-22.png” url=”https:\/\/pubmed.ncbi.nlm.nih.gov\/29246725\/” url_new_window=”on” _builder_version=”4.9.4″ _module_preset=”default” min_height=”186.9px”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.9.4″ _module_preset=”default” min_height=”64px” custom_padding=”0px||0px|||” animation_style=”fade” animation_delay=”600ms” disabled=”on”][et_pb_row _builder_version=”4.9.4″ _module_preset=”default” custom_padding=”||0px|||”][et_pb_column type=”4_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” min_height=”34px” custom_padding=”0px||0px|||” text_font_size_tablet=”” text_font_size_phone=”15px” text_font_size_last_edited=”on|phone”]<\/p>\n

PMID: 29246725\u00a0 \u00a0 \u00a0 \u00a0 \u00a0DOI: 10.1016\/j.jagp.2017.10.010\u00a0<\/strong><\/strong><\/p>\n

ABSTRACT\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0<\/strong><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.9.4″ _module_preset=”default” min_height=”341px” custom_margin=”1px|||||” custom_padding=”12px||0px|||” animation_style=”fade” animation_delay=”600ms” disabled=”on”][et_pb_row _builder_version=”4.9.4″ _module_preset=”default” custom_padding=”0px||0px|||”][et_pb_column type=”4_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” text_font_size_tablet=”” text_font_size_phone=”14px” text_font_size_last_edited=”on|phone” header_font_size_tablet=”” header_font_size_phone=”” header_font_size_last_edited=”on|desktop”]<\/p>\n

Objective: <\/strong>Because curcumin’s anti-inflammatory properties may protect the brain from neurodegeneration, we studied its effect on memory in non-demented adults and explored its impact on brain amyloid and tau accumulation using 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile positron emission tomography (FDDNP-PET).<\/p>\n

Methods: <\/strong>Forty subjects (age 51-84 years) were randomized to a bioavailable form of curcumin (Theracurmin\u00ae containing 90 mg of curcumin twice daily [N = 21]) or placebo (N = 19) for 18 months. Primary outcomes were verbal (Buschke Selective Reminding Test [SRT]) and visual (Brief Visual Memory Test-Revised [BVMT-R]) memory, and attention (Trail Making A) was a secondary outcome. FDDNP-PET signals (15 curcumin, 15 placebo) were determined in amygdala, hypothalamus, medial and lateral temporal, posterior cingulate, parietal, frontal, and motor (reference) regions. Mixed effects general linear models controlling for age and education, and effect sizes (ES; Cohen’s d) were estimated.<\/p>\n

Results: <\/strong>SRT Consistent Long-Term Retrieval improved with curcumin (ES = 0.63, p = 0.002) but not with placebo (ES = 0.06, p = 0.8; between-group: ES = 0.68, p = 0.05). Curcumin also improved SRT Total (ES = 0.53, p = 0.002), visual memory (BVMT-R Recall: ES = 0.50, p = 0.01; BVMT-R Delay: ES = 0.51, p = 0.006), and attention (ES = 0.96, p < 0.0001) compared with placebo (ES = 0.28, p = 0.1; between-group: ES = 0.67, p = 0.04). FDDNP binding decreased significantly in the amygdala with curcumin (ES = -0.41, p = 0.04) compared with placebo (ES = 0.08, p = 0.6; between-group: ES = 0.48, p = 0.07). In the hypothalamus, FDDNP binding did not change with curcumin (ES = -0.30, p = 0.2), but increased with placebo (ES = 0.26, p = 0.05; between-group: ES = 0.55, p = 0.02).<\/p>\n

Conclusions: <\/strong>Daily oral Theracurmin may lead to improved memory and attention in non-demented adults. The FDDNP-PET findings suggest that symptom benefits are associated with decreases in amyloid and tau accumulation in brain regions modulating mood and memory.<\/p>\n

Authors<\/strong>: Gary W Small1 , Prabha Siddarth2 , Zhaoping Li2 , Karen J Miller2 , Linda Ercoli2 , Natacha D Emerson2 , Jacqueline Martinez2 , Koon-Pong Wong2 , Jie Liu2 , David A Merrill2 , Stephen T Chen2 , Susanne M Henning2 , Nagichettiar Satyamurthy2 , Sung-Cheng Huang2 , David Heber2 , Jorge R Barrio2. Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, UCLA Longevity Center, Department of Molecular and Medical Pharmacology, and Center for Human Nutrition, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA. USA 2 Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, UCLA Longevity Center, Department of Molecular and Medical Pharmacology, and Center for Human Nutrition, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA. USA.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.4″ _module_preset=”default” min_height=”66px” custom_padding=”1px|||||”][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.4″ _module_preset=”default” min_height=”184px” custom_margin=”-112px||-269px|||” custom_padding=”||5px|||”][et_pb_row _builder_version=”4.9.4″ _module_preset=”default” min_height=”175px” custom_margin=”-118px|auto||auto||” custom_padding=”0px|||||”][et_pb_column type=”4_4″ _builder_version=”4.9.4″ _module_preset=”default”][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.9.4″ _module_preset=”default” min_height=”310.9px” custom_margin=”96px||-28px|||” custom_padding=”||0px|||” animation_style=”fade” animation_delay=”600ms” disabled=”on”][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.9.4″ _module_preset=”default” custom_margin=”-1px|auto|6px|auto||” custom_padding=”0px||0px|||”][et_pb_column type=”1_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” text_font=”||||||||” text_text_color=”#E09900″ text_font_size=”33px” text_line_height=”1em” header_3_font_size=”33px” text_orientation=”center” custom_margin=”||-1px|0px|false|false” custom_padding=”57px||0px|0px|false|false” header_font_size_last_edited=”off|desktop”]<\/p>\n

November<\/h3>\n

[\/et_pb_text][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” text_text_color=”#E09900″ text_font_size=”33px” header_3_font_size=”55px” min_height=”72px”]<\/p>\n

2020<\/h3>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_image src=”https:\/\/farmolab.es\/wp-content\/uploads\/2021\/04\/Recurso-25.png” url=”https:\/\/pubmed.ncbi.nlm.nih.gov\/33016914\/” url_new_window=”on” _builder_version=”4.9.4″ _module_preset=”default”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.9.4″ _module_preset=”default” min_height=”64px” custom_padding=”0px||0px|||” animation_style=”fade” animation_delay=”600ms” disabled=”on”][et_pb_row _builder_version=”4.9.4″ _module_preset=”default” custom_padding=”||0px|||”][et_pb_column type=”4_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” min_height=”34px” custom_padding=”0px||0px|||” text_font_size_tablet=”” text_font_size_phone=”15px” text_font_size_last_edited=”on|phone”]<\/p>\n

PMID: 33016914\u00a0 \u00a0 \u00a0 \u00a0 \u00a0PMCID: PMC7739965<\/strong><\/p>\n

DOI: 10.3233\/JAD-200711\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 <\/strong><\/strong><\/p>\n

ABSTRACT\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0<\/strong><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.9.4″ _module_preset=”default” min_height=”341px” custom_margin=”1px|||||” custom_padding=”12px||0px|||” animation_style=”fade” animation_delay=”600ms” disabled=”on”][et_pb_row _builder_version=”4.9.4″ _module_preset=”default” custom_margin=”|auto|-41px|auto||” custom_padding=”6px|||||”][et_pb_column type=”4_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” text_orientation=”justified” text_font_size_tablet=”” text_font_size_phone=”14px” text_font_size_last_edited=”on|phone”]<\/p>\n

Background: <\/strong>Alzheimer’s disease (AD) is increasingly prevalent and over 99% of drugs developed for AD have failed in clinical trials. A growing body of literature suggests that potent inhibitors of tumor necrosis factor-\u03b1 (TNF-\u03b1) have potential to improve cognitive performance.<\/p>\n

Objective: <\/strong>In this review, we summarize the evidence regarding the potential for TNF-\u03b1 inhibition to prevent AD and improve cognitive function in people at risk for dementia.<\/p>\n

Methods: <\/strong>We conducted a literature review in PubMed, screening all articles published before July 7, 2019 related to TNF blocking agents and curcumin (another TNF-\u03b1 inhibitor) in the context of AD pathology. The keywords in the search included: AD, dementia, memory, cognition, TNF-\u03b1, TNF inhibitors, etanercept, infliximab, adalimumab, golimumab, and curcumin.<\/p>\n

Results: <\/strong>Three large epidemiology studies reported etanercept treated patients had 60 to 70% lower odds ratio (OR) of developing AD. Two small-randomized control trials (RCTs) demonstrated an improvement in cognitive performance for AD patients treated with etanercept. Studies using animal models of dementia also reported similar findings with TNF blocking agents (etanercept, infliximab, adalimumab, Theracurmin), which appeared to improve cognition. A small human RCT using Theracurmin, a well-absorbed form of curcumin that lowers TNF-\u03b1, showed enhanced cognitive performance and decreased brain levels of amyloid-\u03b2 plaque and tau tangles.<\/p>\n

Conclusion: <\/strong>TNF-\u03b1 targeted therapy is a biologically plausible approach to the preservation of cognition, and warrants larger prospective RCTs to further investigate potential benefits in populations at risk of developing AD.<\/p>\n

Authors: <\/strong>Noel Torres-Acosta1 , James H O’Keefe2 , Evan L O’Keefe3 , Richard Isaacson4 , Gary Small5. (1University of Kansas Medical Center, Kansas City, KS, USA. 2 Saint Luke’s Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, MO, USA. 3 Tulane Medical Center, New Orleans, LA, USA. 4 Alzheimer’s Prevention Clinic, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA. 5 UCLA Longevity Center, Los Angeles, CA, USA.).<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.9.4″ _module_preset=”default” min_height=”310.9px” custom_margin=”||-28px|||” custom_padding=”||0px|||” animation_style=”fade” animation_delay=”600ms” disabled=”on”][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.9.4″ _module_preset=”default” custom_margin=”-1px|auto|6px|auto||” custom_padding=”0px||0px|||”][et_pb_column type=”1_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” text_font=”||||||||” text_text_color=”#E09900″ text_font_size=”33px” text_line_height=”1em” header_3_font_size=”33px” text_orientation=”center” custom_margin=”||-1px|0px|false|false” custom_padding=”57px||0px|0px|false|false” header_font_size_last_edited=”off|desktop”]<\/p>\n

May<\/h3>\n

[\/et_pb_text][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” text_text_color=”#E09900″ text_font_size=”33px” header_3_font_size=”55px” min_height=”72px”]<\/p>\n

2019<\/h3>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_image src=”https:\/\/farmolab.es\/wp-content\/uploads\/2021\/04\/Recurso-23.png” url=”https:\/\/pubmed.ncbi.nlm.nih.gov\/32546987\/” url_new_window=”on” _builder_version=”4.9.4″ _module_preset=”default”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.9.4″ _module_preset=”default” min_height=”64px” custom_padding=”0px||0px|||” animation_style=”fade” animation_delay=”600ms” disabled=”on”][et_pb_row _builder_version=”4.9.4″ _module_preset=”default” custom_padding=”||0px|||”][et_pb_column type=”4_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” min_height=”34px” custom_padding=”0px||0px|||” text_font_size_tablet=”” text_font_size_phone=”15px” text_font_size_last_edited=”on|phone”]<\/p>\n

\u00a0PMID: 32546987.\u00a0 \u00a0 \u00a0 \u00a0 \u00a0PMCID: PMC7245427\u00a0 \u00a0 \u00a0 <\/strong><\/p>\n

DOI: 10.2147\/CIA.S252229\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/strong><\/strong><\/p>\n

ABSTRACT\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0<\/strong><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.9.4″ _module_preset=”default” custom_padding=”1px|||||” animation_style=”fade” animation_delay=”600ms” disabled=”on”][et_pb_row _builder_version=”4.9.4″ _module_preset=”default” custom_margin=”|auto|-41px|auto||”][et_pb_column type=”4_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” text_font_size_tablet=”” text_font_size_phone=”14px” text_font_size_last_edited=”on|desktop”]<\/p>\n

Chemobrain is one of the problems that may arise during or after treatment and there is currently no specific treatment for this condition. <\/span><\/p>\n

Our case was a 76-year-old female patient who presented to our clinic with complaints of forgetfulness that did not affect daily living activities for the last year. Breast cancer was diagnosed in 2013 and she has been receiving anastrozole treatment for 6 years after local mass excision surgery and radiotherapy. <\/span><\/p>\n

After a comprehensive geriatric evaluation, cognitive impairment due to systemic cancer therapy was detected and treatment was started with Theracurmin 90 mg twice a day therapy. After 3-months of Theracurmin therapy, she had no cognitive improvement during the follow-up. <\/span><\/p>\n

This case report demonstrated that Theracurmin treatment may be a new option for chemobrain.<\/span><\/p>\n

<\/span><\/p>\n

Authors<\/strong>: Neziha Erken1 , Fatma Sena Dost Gunay1 , Pinar Soysal2 , Ahmet Turan Isik1 (1Department of Geriatric Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey. 2 Department of Geriatric Medicine, Bezmialem Vakif University, Faculty of Medicine, Istanbul, Turkey).<\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.9.4″ _module_preset=”default” min_height=”310.9px” custom_margin=”||-28px|||” custom_padding=”||0px|||” animation_style=”fade” animation_delay=”600ms” disabled=”on”][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.9.4″ _module_preset=”default” custom_margin=”-1px|auto|6px|auto||” custom_padding=”0px||0px|||”][et_pb_column type=”1_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” text_font=”||||||||” text_text_color=”#E09900″ text_font_size=”33px” text_line_height=”1em” header_3_font_size=”33px” text_orientation=”center” custom_margin=”||-1px|0px|false|false” custom_padding=”57px||0px|0px|false|false” header_font_size_last_edited=”off|desktop”]<\/p>\n

May<\/h3>\n

[\/et_pb_text][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” text_text_color=”#E09900″ text_font_size=”33px” header_3_font_size=”55px” min_height=”72px”]<\/p>\n

2019<\/h3>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_image src=”https:\/\/farmolab.es\/wp-content\/uploads\/2021\/04\/Recurso-24.png” url=”https:\/\/pubmed.ncbi.nlm.nih.gov\/31006181\/” url_new_window=”on” _builder_version=”4.9.4″ _module_preset=”default”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.9.4″ _module_preset=”default” min_height=”64px” custom_padding=”0px||0px|||” animation_style=”fade” animation_delay=”600ms” disabled=”on”][et_pb_row _builder_version=”4.9.4″ _module_preset=”default” custom_padding=”||0px|||”][et_pb_column type=”4_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” min_height=”34px” custom_padding=”0px||0px|||” text_font_size_tablet=”” text_font_size_phone=”15px” text_font_size_last_edited=”on|phone”]<\/p>\n

\u00a0PMID: 31006181.\u00a0 \u00a0 \u00a0 \u00a0 \u00a0PMCID: PMC6513190\u00a0 \u00a0 \u00a0\u00a0<\/strong><\/p>\n

DOI:\u00a0 10.4062\/biomolther.2019.046<\/strong><\/strong><\/p>\n

ABSTRACT\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0<\/strong><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.9.4″ _module_preset=”default” custom_padding=”1px|||||” animation_style=”fade” animation_delay=”600ms” disabled=”on”][et_pb_row _builder_version=”4.9.4″ _module_preset=”default” custom_margin=”|auto|-41px|auto||” custom_padding=”6px|||||”][et_pb_column type=”4_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” text_font_size=”14px”]<\/p>\n

As the elderly population is increasing, Alzheimer’s disease (AD) has become a global issue and many clinical trials have been conducted to evaluate treatments for AD. As these clinical trials have been conducted and have failed, the development of new theraphies for AD with fewer adverse effects remains a challenge. <\/span><\/p>\n

In this study, we examined the effects of Theracurmin on cognitive decline using 5XFAD mice, an AD mouse model. Theracurmin is more bioavailable form of curcumin, generated with submicron colloidal dispersion. <\/span><\/p>\n

Mice were treated with Theracurmin (100, 300 and 1,000 mg\/kg) for 12 weeks and were subjected to the novel object recognition test and the Barnes maze test. Theracurmin-treated mice showed significant amelioration in recognition and spatial memories compared those of the vehicle-treated controls. In addition, the antioxidant activities of Theracurmin were investigated by measuring the superoxide dismutase (SOD) activity, malondialdehyde (MDA) and glutathione (GSH) levels. The increased MDA level and decreased SOD and GSH levels in the vehicle-treated 5XFAD mice were significantly reversed by the administration of Theracurmin. <\/span><\/p>\n

Moreover, e<\/span>e observed that Theracurmin administration elevated the expression levels of synaptic components, including synaptophysin and post synaptic density protein 95, and decreased the expression levels of ionized calcium-binding adapter molecule 1 (Iba-1), a marker of activated microglia. <\/span><\/p>\n

These results suggest that Theracurmin ameliorates cognitive function by increasing the expression of synaptic components and by preventing neuronal cell damage from oxidative stress or from the activation of microglia. Thus, <\/span><\/p>\n

Theracurmin would be useful for treating the cognitive dysfunctions observed in AD.<\/span><\/p>\n

<\/span><\/p>\n

Authors<\/strong>: Jihyun Kim1 , Jaehoon Kim1 , Zhouchi Huang2 , Nayeon Goo1 , Ho Jung Bae1 , Yongwoo Jeong1 , Ho Jae Park3 , Mudan Cai1 , Kyungnam Cho1 , Seo Yun Jung1 , Soo Kyung Bae2 , Jong Hoon Ryu1-3. (1Departments of Life and Nanopharmaceutical Science, Kyung Hee University, Seoul 02447, Republic of Korea. 2 College of Pharmacy and Integrated Research Institute of Parmaceutical Sciences, The Catholic University of Korea, Bucheon 14662, Republic of Korea. 3Departments of Oriental Pharmaceutical Science, Kyung Hee University, Seoul 02447, Republic of Korea).<\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.9.4″ _module_preset=”default” min_height=”310.9px” custom_margin=”||-28px|||” custom_padding=”||0px|||” animation_style=”fade” animation_delay=”600ms” disabled=”on”][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.9.4″ _module_preset=”default” custom_margin=”-1px|auto|6px|auto||” custom_padding=”0px||0px|||”][et_pb_column type=”1_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” text_font=”||||||||” text_text_color=”#E09900″ text_font_size=”33px” text_line_height=”1em” header_3_font_size=”33px” text_orientation=”center” custom_margin=”||-1px|0px|false|false” custom_padding=”57px||0px|0px|false|false” header_font_size_last_edited=”off|desktop”]<\/p>\n

May<\/h3>\n

[\/et_pb_text][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” text_text_color=”#E09900″ text_font_size=”33px” header_3_font_size=”55px” min_height=”72px”]<\/p>\n

2014<\/h3>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_image src=”https:\/\/farmolab.es\/wp-content\/uploads\/2021\/04\/Recurso-26.png” url=”https:\/\/pubmed.ncbi.nlm.nih.gov\/24637610\/” url_new_window=”on” _builder_version=”4.9.4″ _module_preset=”default”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.9.4″ _module_preset=”default” min_height=”64px” custom_padding=”0px||0px|||” animation_style=”fade” animation_delay=”600ms” disabled=”on”][et_pb_row _builder_version=”4.9.4″ _module_preset=”default” custom_padding=”||0px|||”][et_pb_column type=”4_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” min_height=”34px” custom_padding=”0px||0px|||” text_font_size_tablet=”” text_font_size_phone=”15px” text_font_size_last_edited=”on|phone”]<\/p>\n

\u00a0PMID: 24637610.\u00a0 \u00a0 \u00a0 \u00a0<\/strong><\/p>\n

DOI: 10.1039\/c4fo00009a<\/span><\/strong><\/strong><\/p>\n

ABSTRACT\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0<\/strong><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.9.4″ _module_preset=”default” custom_padding=”1px|||||” animation_style=”fade” animation_delay=”600ms” disabled=”on”][et_pb_row _builder_version=”4.9.4″ _module_preset=”default” custom_margin=”|auto|-41px|auto||” custom_padding=”6px|||||”][et_pb_column type=”4_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” text_font_size_tablet=”” text_font_size_phone=”14px” text_font_size_last_edited=”on|desktop”]<\/p>\n

Curcumin, a polyphenolic compound has several pharmacological activities, such as anticancer, anti-inflammatory and antioxidant effects. However, curcumin shows poor oral bioavailability. <\/span><\/p>\n

The purpose of this study was to investigate the protective effects of highly bioavailable curcumin, Theracurmin(\u00ae), and curcumin, against sodium nitroprusside (SNP)-induced oxidative damage in mice brain. Intrastriatal microinjection of Theracurmin(\u00ae) or curcumin with SNP significantly protected against SNP-induced brain damage and motor dysfunction.<\/span><\/p>\n

Oral administration of Theracurmin(\u00ae) (1 and 3 g kg(-1), containing 100 and 300 mg kg(-1) curcumin, respectively) significantly protected against SNP-induced brain damage and motor dysfunction. However, oral administration of 300 mg kg(-1) curcumin did not protect against motor dysfunction induced by SNP. <\/span><\/p>\n

These results suggest that curcumin and Theracurmin(\u00ae) have protective effects against SNP-induced oxidative damage. Moreover, <\/span>Oral administration of Theracurmin(\u00ae), had more potency in protecting against brain damage, suggesting a higher bioavailability of Theracurmin(\u00ae) following oral administration.<\/span><\/p>\n

<\/span><\/p>\n

Authors<\/strong>: Qand Agha Nazari, Yuki Takada-Takatori, Tadashi Hashimoto, Atsushi Imaizumi, Yasuhiko Izumi, Akinori Akaike, Toshiaki Kume. (Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Shimoadachi-cho, Sakyo-Ku, Kyoto 606-8501, Japan)..<\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.4″ _module_preset=”default” custom_padding=”||0px|||”][et_pb_row _builder_version=”4.9.4″ _module_preset=”default”][et_pb_column _builder_version=”4.9.4″ _module_preset=”default” type=”4_4″][et_pb_divider _builder_version=”4.9.4″ _module_preset=”default” show_divider=”off” hover_enabled=”0″ sticky_enabled=”0″][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.4.5″ use_background_color_gradient=”on” background_color_gradient_start=”#d5611b” background_color_gradient_end=”#ffffff” background_color_gradient_direction=”90deg” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” collapsed=”on”][et_pb_row _builder_version=”4.4.5″ custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false”][et_pb_column type=”4_4″ _builder_version=”4.4.5″][et_pb_cta title=”BIBLIOGRAPHY” _builder_version=”4.9.4″ header_font=”|||on|||||” header_font_size=”52px” body_font_size=”13px” background_color=”rgba(0,0,0,0)” text_orientation=”left” custom_margin=”||||false|false” custom_padding=”20px|0px|0px|0px|false|false” animation_style=”slide” animation_direction=”right” header_font_size_tablet=”” header_font_size_phone=”32px” header_font_size_last_edited=”on|phone”][\/et_pb_cta][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.4.5″ collapsed=”off”][et_pb_row _builder_version=”4.4.5″ custom_margin=”||||false|false” custom_padding=”||||false|false”][et_pb_column type=”4_4″ _builder_version=”4.4.5″][et_pb_text _builder_version=”4.4.5″ text_font_size=”14px” animation_style=”slide” animation_direction=”bottom”]<\/p>\n

Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem., 280, 5892\u20135901 (2005).Ono, K., Hasegawa, K., Naiki, H., Yamada, M., 2004. Curcumin has potent anti-amyloidogenic effects for Alzheimer\u2019s \u001f-amyloid fibrils in vitro. J. Neurosci. Res. 750, 742\u2013750. Kulkarni SK, Bhutanio. Gary W. Small, M.D., Prabha Siddarth, Ph.D., Zhaoping Li, M.D., Ph.D., Karen J. Miller, Ph.D., Linda Ercoli, Ph.D., Natacha D. Emerson, M.A., Jacqueline Martinez, M.B.A., M.S., Koon-Pong Wong, Ph.D., Jie Liu, Ph.D., David A. Merrill, M.D., Ph.D., Stephen T. Chen, M.D., Susanne M. Henning, Ph.D., R.D., Nagichettiar Satyamurthy, Ph.D., Sung-Cheng Huang, D.Sc., David Heber, M.D., Ph.D., Jorge R. Barrio, Ph.D. Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial.Am J Geriatr Psychiatry 26:3,March 2018. Jihyun Kim, Jaehoon Kim, Zhouchi Huang, Nayeon Goo, Ho Jung Bae, Yongwoo Jeong, Ho Jae Park, Mudan Cai, Kyungnam Cho, Seo Yun Jung, Soo Kyung Bae and Jong Hoon Ryu. Theracurmin Ameliorates Cognitive Dysfunctions in 5XFAD Mice by Improving Synaptic Function and Mitigating Oxidative Stress. Biomol Ther 27(3), 327-335 (2019). Gary W. Small, M.D., Vladimir Kepe, Ph.D., Linda M. Ercoli, Ph.D., Prabha Siddarth, Ph.D., Susan Y. Bookheimer, Ph.D., Karen J. Miller, Ph.D., Helen Lavretsky, M.D., Alison C. Burggren, Ph.D., Greg M. Cole, Ph.D., Harry V. Vinters, M.D., Paul M. Thompson, Ph.D., S.-C. Huang, Ph.D., N. Satyamurthy, Ph.D., Michael E. Phelps, Ph.D., and Jorge R. Barrio, Ph.D. PET of Brain Amyloid and Tau in Mild Cognitive Impairment. N Engl J Med 2006;355:2652-63. Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, Wada H, Katanasaka Y, Kakeya H, Fujita M, Hasegawa K, Morimoto T. Innovative preparation of curcumin for improved oral bioavailability. Biol. Pharm. Bull., 34, 660\u2013665 (2011). 23). Sunagawa Y, Hirano S, Katanasaka Y, Miyazaki Y, Funamoto M, Okamura N, Hojo Y, Suzuki H, Doi O, Yokoji T, Morimoto E, Takahashi T, Ozawa H, Imaizumi A, Ueno M, Kakeya H, Shimatsu A, Wada H, Hasegawa K, Morimoto T. Colloidal submicron-particle curcumin exhibits high absorption efficiency\u2014a double-blind, 3-way crossover study. J. Nutr. Sci. Vitaminol., 61, 37\u201344 (2015). Kanai M, Otsuka Y, Otsuka K, Sato M, Nishimura T, Mori Y, Kawaguchi M, Hatano E, Kodama Y, Matsumoto S, Murakami Y, Imaizumi A, Chiba T, Nishihira J, Shibata H. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemother. Pharmacol., 71, 1521\u20131530 (2013). Takahashi M, Suzuki K, Kim HK, Otsuka Y, Imaizumi A, Miyashita M, Sakamoto S. Effects of curcumin supplementation on exercise-induced oxidative stress in humans. Int. J. Sports Med., 35, 469\u2013475 (2014). Imaizumi A. Highly bioavailable curcumin (Theracurmin): its development and clinical application. PharmaNutrition, 3, 123\u2013130 (2015). Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res., 67, 3853\u20133861 1524 (2007). Small G. Oral Presentation at the American Society for Nutrition. Boston MA 2018. Erken N., et al. The Effect of Theracurmin on Cognitive Function\u00a0<\/span>in an Older Patient with Chemobrain.\u00a0\u00a0<\/span>Clinical Interventions in Aging 2020:15 691-693.\u00a0\u00a0<\/span>Noel Torres-Acosta, James H., O\u2019Keefe, Evan L. O\u2019Keefe, Richard Isaacson<\/span>\u00a0<\/span>and Gary Small.\u00a0\u00a0<\/span>Therapeutic Potential of TNF-<\/span> <\/span>Inhibition\u00a0<\/span>for Alzheimer\u2019s Disease Prevention. Journal of Alzheimer\u2019s Disease, vol. Pre-press, no. Pre-press, pp. 1-8, 2020. DOI:10.3233\/JAD-200711.<\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

Cognex\u00ae 30 Capsules used for States related to age, cognitive impairment and memory. Cognex\u00ae 30 Capsules Cognitive functions are mental processes that allow us to perform any task. They include the ability to think, concentrate, pay attention, memorize, transform, elaborate and retrieve information to function properly. Cognitive function can begin to deteriorate naturally around […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":""},"yoast_head":"\n